| Identification | Back Directory | [Name]
DOTA-BIM-23014:DOTA-Lanreotide | [CAS]
213187-44-1 | [Synonyms]
DOTA-Lanreotide
DOTA-Lanreotide acetate
DOTA-BIM-23014:DOTA-Lanreotide
L-Threoninamide, 3-(2-naphthalenyl)-N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-alanyl-Lcysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-Lcysteinyl-,cyclic (2)-disulfide
L-Threoninamide, 3-(2-naphthalenyl)-N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2 → 7) disulfide | [Molecular Formula]
C70H95N15O17S2
| [MOL File]
213187-44-1.mol | [Molecular Weight]
1482.72 |
| Chemical Properties | Back Directory | [Appearance]
Colourless to off-white lyophilised powder | [Boiling point ]
1750.5±65.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [pka]
1.83±0.10(Predicted) | [Sequence]
{DOTA}-{d-2Nal}-Cys-Tyr-{d-Trp}-Lys-Val-Cys-Thr (disulfide bridge:Cys2-Cys7) |
| Hazard Information | Back Directory | [Chemical Properties]
Colourless to off-white lyophilised powder | [Uses]
DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy[1]. |
|
|